Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Namodenoson

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Can-Fite Secures Israeli Patent for Namodenoson Anti-Obesity Use
    Can-Fite Secures Israeli Patent for Namodenoson Anti-Obesity Use

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257054/0/en/Can-Fite-Expands-Namodenoson-anti-Obesity-Franchise-with-Israeli-Patent-Allowance.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Can-Fite's Namodenoson Succeeds in Ph 2A Pancreatic Cancer Study
    Can-Fite's Namodenoson Succeeds in Ph 2A Pancreatic Cancer Study

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249198/0/en/Can-Fite-s-Namodenoson-Successfully-Meets-Primary-Endpoint-in-Phase-2a-Pancreatic-Cancer-Study.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share
    Can-Fite Granted Canadian Patent For Namodenoson As Anti-Obesity
    Can-Fite Granted Canadian Patent For Namodenoson As Anti-Obesity

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234404/0/en/Can-Fite-Receives-Canadian-Patent-Allowance-for-Namodenoson-as-an-Anti-Obesity-Therapy.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    Cirrhosis Patient Get Liver Transplant After Namodenoson
    Cirrhosis Patient Get Liver Transplant After Namodenoson

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232840/0/en/Can-Fite-Patient-with-Decompensated-Liver-Cirrhosis-Successfully-Undergoes-Liver-Transplantation-Following-Treatment-with-Namodenoson.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Can-Fite Wraps Namodenoson Phase 2a Trial in Pancreatic Cancer
    Can-Fite Wraps Namodenoson Phase 2a Trial in Pancreatic Cancer

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221562/0/en/Can-Fite-Completes-Patient-Enrollment-in-Phase-2a-Pancreatic-Cancer-Study-of-Namodenoson.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Can-Fite Provides Update On Clinical And Financial Status
    Can-Fite Provides Update On Clinical And Financial Status

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206339/0/en/Can-Fite-Provides-Update-on-Clinical-and-Financial-Status.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.